Global Cord Blood (Global Cord Blood) Debt-to-Equity

: 0.00 (As of Mar. 2022)

View and export this data going back to 2007. Start your Free Trial

Global Cord Blood's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2022 was $0.0 Mil. Global Cord Blood's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2022 was $0.0 Mil. Global Cord Blood's Total Stockholders Equity for the quarter that ended in Mar. 2022 was $769.1 Mil. Global Cord Blood's debt to equity for the quarter that ended in Mar. 2022 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Global Cord Blood's Debt-to-Equity or its related term are showing as below:

CORBF's Debt-to-Equity is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 0.24
* Ranked among companies with meaningful Debt-to-Equity only.

Global Cord Blood Debt-to-Equity Historical Data

The historical data trend for Global Cord Blood's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Global Cord Blood Annual Data

Trend

Mar13

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Debt-to-Equity

Global Cord Blood Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Debt-to-Equity																-	-	-	-	-

Competitive Comparison

For the Diagnostics & Research subindustry, Global Cord Blood's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Global Cord Blood Debt-to-Equity Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Global Cord Blood's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Global Cord Blood's Debt-to-Equity falls into.

Global Cord Blood Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Global Cord Blood's Debt to Equity Ratio for the fiscal year that ended in Mar. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.023	+	0)	/	769.05
	=	0.00

Global Cord Blood's Debt to Equity Ratio for the quarter that ended in Mar. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.023	+	0)	/	769.05
	=	0.00

Global Cord Blood (OTCPK:CORBF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Global Cord Blood Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Global Cord Blood's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Global Cord Blood (Global Cord Blood) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Global Cord Blood Corp (OTCPK:CORBF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Garden Road, 48th Floor, Bank of China Tower, Central, Hong Kong, HKG

Website

http://www.globalcordbloodcorp.com

Global Cord Blood Corp provides cord blood banking services. The company provides cord blood processing and storage services for expectant parents interested in capturing the evolving medical treatments and technologies such as cord blood transplants.

Executives

Kent C Mccarthy	10 percent owner, other: Mbr 13(d) grp own 10% plus	930 TAHOE BLVD., 802-281, INCLINE VILLAGE NV 89451
Jayhawk Private Equity Fund Ii Lp	10 percent owner	5410 WEST 61ST PLACE, SUITE 100, MISSION KS 66205
7-2010 Grat 5 Under Kent C. Mccarthy Grat Tr Dtd 4-23-2010	other: 13 (d) group owning > 10%	7335 COTTONWOOD DRIVE, SHAWNEE KS 66216
7-2010 Grat 6 Under Kent C Mccarthy Grat Tr Dtd 4-23-2010	10 percent owner, other: Member of 13(d) group owning m	7335 COTTONWOOD, SHAWNEE KS 66216
Mccarthy Family Sd, Llc	10 percent owner, other: 13 (d) group owning > 10%	7335 COTTONWOOD DRIVE, SHAWNEE KS 66216
Jhab Fund Ii, Llc	other: 13(d) group owning > 10%	7335 COTTONWOOD DRIVE, SHAWNEE KS 66216
Jhab Management Ii, Llc	other: 13(d) group owning > 10%	7335 COTTONWOOD DRIVE, SHAWNEE KS 66216
Jcf Co Lf, L.p.	other: 13(d) group owning > 10%	930 TAHOE BLVD., 802-281, INCLINE VILLAGE NV 89451
Jayhawk Capital Management Llc	other: Member of the group	13021 W 74TH ST, SHAWNEE KS 66216
Jayhawk China Fund Cayman Ltd	other: Member of the group	930 TAHOE BLVD., 802-281, INCLINE VILLAGE NV 89451
Jayhawk Private Equity Gp Ii, L.p.	10 percent owner	5410 WEST 61ST PLACE, SUITE 100, MISSION KS 66205
Jayhawk Private Equity, Llc	10 percent owner	5410 WEST 61ST PLACE, SUITE 100, MISSION KS 66205